US 12,251,432 B2
Biomarkers and immunogenic compositions for filarial parasites
Sara Lustigman, New York, NY (US); Thomas B. Nutman, Bethesda, MD (US); and Sasisekhar Bennuru, Bethesda, MD (US)
Assigned to New York Blood Center, Inc., New York, NY (US); and The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by New York Blood Center, Inc., New York, NY (US); and The United States of America, as Represented by the Secretary, Department of Health and Human Services, Rockville, MD (US)
Filed on Oct. 21, 2020, as Appl. No. 17/076,616.
Application 17/076,616 is a division of application No. 16/090,013, abandoned, previously published as PCT/US2017/025554, filed on Mar. 31, 2017.
Claims priority of provisional application 62/317,243, filed on Apr. 1, 2016.
Prior Publication US 2021/0046170 A1, Feb. 18, 2021
Int. Cl. A61K 39/00 (2006.01); A61P 33/10 (2006.01); C07K 14/435 (2006.01); C07K 16/18 (2006.01); G01N 33/53 (2006.01)
CPC A61K 39/0003 (2013.01) [A61P 33/10 (2018.01); C07K 14/4354 (2013.01); C07K 16/18 (2013.01); G01N 33/5308 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/70 (2013.01)] 10 Claims
 
1. An immunogenic composition for administration to a canine subject, the composition comprising isolated Dirofilaria immitis proteins consisting of:
a first protein having at least 95% sequence identity to SEQ ID NO:48 and a second protein having at least 95% sequence identity to the full length mature amino acid sequence of SEQ ID NO: 49; and
an adjuvant.